Professional
Added to YB: 2024-09-05
Pitch date: 2024-07-11
RGEN [bullish]
Repligen Corporation
+24.74%
current return
Author Info
No bio for this author
Company Info
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.6B
Pitch Price
$126.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.33
P/E
6.0K
EV/Sales
12.03
Sector
Life Sciences Tools and Services
Category
turnaround
Columbia Acorn Fund Portfolio Holding: Repligen Corporation
RGEN: Bioprocessing supplier facing COVID comps, destocking, pharma caution & CEO change. Market overstates transitory issues. Large position maintained. Stock poised for quick rebound on industry recovery signs. Innovative solutions in fast-growing healthcare sector.
Read full article (1 min)